Tuesday, October 22, 2013 11:17:35 AM
When you look at the Aileron PRs they claim a superior approach because the stapled peptides allow them to modulate both MDM2 and MDMX which are the "big two" protein regulators of p53. MDM2 is regarded as the primary inhibitory pathway because it acts on p53 in more ways than MDMX. MDM2 inhibits through 2 mechanisms (inhibition and degradation) while MDMX inhibits p53 but does not degrade it.
Kevetrin does not directly modulate MDMX so this would appear to give the stapled peptide approach an advantage over K, which only modulates MDM2. To quote: " The inability of MDM2 inhibitors to target MDMX-p53 interaction or induce MDMX degradation prevents full activation of P53, imparting resistance to MDM2 inhibitors." It also is important to note that MDM2 and MDMX interact with each other and those interactions allow MDM2 to in turn degrade MDMX. But if Kevetrin has downregulated MDM2 that is not going to happen.
So score a point for Roche/Aileron.
But before we dismay too much there are two important points to consider: First, Kevetrin is in human trials while Roche/Aileron is claiming they will start a human trial in 2014. The transition from preclinical to human trials is tricky and who knows if they can pull it off with a candidate that is both efficacious and non-toxic.
The second point is a huge advantage for Kevetrin as it does something which the Aileron drug candidate does not. Kevetrin affects both wild type and mutated p53. The Roche/Aileron drug affects only wild type P53. This is quite significant as mutant p53 may promote tumor progression and resistance to therapy. Consider these quotes:
"p53 mutants that promote tumor progression and resistance to therapy become the most common prognostic indicator for both cancer recurrence and death."
or this:
"Introduction of wild type P53 by gene therapy can correct loss of function in tumor suppression, but cannot diminish the oncogenic effects of mutant p53 on tumors. "
So the fact that K is in human trials and addresses the type of P53 mutants that harbor "the most common prognostic indicator for both cancer recurrence and death" garners Kevetrin a couple of points. And there is this too - the following quote hints that Kevetrin may still have some effect on MDMX because CTIX data indicates K activates Bax.
"Thus, the combination of MDM2 inhibitors with chemotherapeutic agents such as doxorubicin, which induces MDMX degradation, or with a BH3 mimetic ABT-737, WHICH ACTIVATES Bax AND OVERCOMES MDMX-MEDIATED SUPPRESSION OF p53 FUNCTION, MIGHT HAVE THERAPEUTIC VALUE.
If that bolded section is indicative that Bax activated by Kevetrin would provide an indirect means to degrade MDMX then any advantage of the stapled peptide approach of Roche/ Aileron disappears. And that might occur without the combo therapy described in the quote but by the use of K by itself if the Bax expression CTIX has noted is significant enough to do the job. But this is speculative on my part as there is no direct quote from CTIX regarding any effect on MDMX.
To me it is obvious which approach holds more promise and that is where I have put my money. It would seem even a less robust activation of P53 partially inhibited by the lack of downregulation of MDMX is better than no defense against an oncogenic mutated P53 which will only buy some time before resistance and recurrence. So CTIX is the most advanced candidate and, in my opinion, has an important advantage that outweighs the MDMX issue.
For what it is worth. My degree in biology is 40 years old - a time I refer to as the "pre-genetic era" LOL. Still, I like this stuff and my conclusion favoring K is what I take from delving into the science of the two different approaches. But you can draw your own conclusions.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM